A

little-known drug company announced modestly encouraging results for its experimental Alzheimer’s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.

A mid-stage study by a tiny company wouldn’t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug — derived from a bushy, hermaphroditic sea creature — takes a novel approach.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Whether bryostatin-1 is successful in treating Alzheimers, the jury is still out. Maybe it will maybe it will not. Right now it is my informed belief that Anavex 2-73 is the front runner, a potential disease modifier, safe and more effective than the current standard of care.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X